Automation and quality control in the coagulation laboratory

Area of Science:

• Coagulation and hemostasis research.
• Clinical laboratory diagnostics.
• Biotechnology and molecular biology.

Background:

• Hemostasis involves complex interactions between coagulation, fibrinolysis, platelets, endothelium, and leukocytes.
• Coagulation disorders are frequently associated with various disease states.
• Traditional hemostasis assays have limitations in providing detailed, quantitative, and physiologically relevant evaluations.

Purpose of the Study:

• To highlight advancements in hemostasis laboratory diagnostics.
• To introduce a two-step diagnostic approach: global screening and targeted analysis.
• To emphasize the role of new methodologies in identifying genetic predispositions and early disease stages.

Main Methods:

• Development of new global test systems for more detailed hemostasis evaluation.
• Implementation of sensitive and specific assays for individual enzymes, inhibitors, and molecular markers.
• Utilization of advanced analytical instruments including automated analyzers, ELISA, RIA, and flow cytometers.

Main Results:

• New global tests offer more quantitative and physiologically relevant hemostasis evaluations.
• Molecular markers of hemostatic activation provide early evidence of thrombotic or fibrinolytic aberrations.
• Technological advances have expanded the scope of coagulation laboratory testing.

Conclusions:

• Modern hemostasis testing facilitates early identification of genetic predispositions and subclinical disease stages.
• New methodologies enable targeted prophylactic and therapeutic interventions for hemostatic conditions.
• Technological integration from clinical chemistry, immunology, and biotechnology has revolutionized coagulation analysis.